Dr. Adam S. Kittai, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies Lymphoma
Studies T-Lymphoblastic Leukemia/Lymphoma
3 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Adam S. Kittai, MD is currently running
Zanubrutinib + CAR T-Cell Therapy
for Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop the spread of cancer. Liso-cel is a type of treatment known as chimeric antigen receptor (CAR) T cell therapy. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving zanubrutinib and liso-cell together may kill more cancer cells in patients with Richter's syndrome.
Recruiting1 award Phase 2
Polatuzumab Vedotin + Chemotherapy
for Richter Syndrome
This trial tests a combination of drugs to treat patients with a severe type of lymphoma. The treatment aims to kill cancer cells and boost the immune system. Patients will be monitored closely for an extended period to see how well they respond.
Recruiting1 award Phase 210 criteria
More about Adam S. Kittai, MD
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Adam S. Kittai, MD has experience with
- Lisocabtagene Maraleucel
- Zanubrutinib
- Acalabrutinib
- Obinutuzumab
- Venetoclax
- Cyclophosphamide
Breakdown of trials Adam S. Kittai, MD has run
Lymphoma
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam S. Kittai, MD specialize in?
Adam S. Kittai, MD focuses on Lymphoma and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Adam S. Kittai, MD currently recruiting for clinical trials?
Yes, Adam S. Kittai, MD is currently recruiting for 3 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Adam S. Kittai, MD has studied deeply?
Yes, Adam S. Kittai, MD has studied treatments such as Lisocabtagene Maraleucel, Zanubrutinib, Acalabrutinib.
What is the best way to schedule an appointment with Adam S. Kittai, MD?
Apply for one of the trials that Adam S. Kittai, MD is conducting.
What is the office address of Adam S. Kittai, MD?
The office of Adam S. Kittai, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.